2,2'-bis[[(3,5-dimethylpyrazol-1-yl)methyl]amino]-1,1'-biphenyl | 850482-72-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,2'-bis[[(3,5-dimethylpyrazol-1-yl)methyl]amino]-1,1'-biphenyl
• 英文别名: N-[(3,5-dimethylpyrazol-1-yl)methyl]-2-[2-[(3,5-dimethylpyrazol-1-yl)methylamino]phenyl]aniline
• CAS: 850482-72-3
• 化学式: C₂₄H₂₈N₆
• 分子量: 400.527
• InChiKey: PMWHNOHCRNDHSO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  59.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  copper(II) choride dihydrate 、 2,2'-bis[[(3,5-dimethylpyrazol-1-yl)methyl]amino]-1,1'-biphenyl 以 甲醇 为溶剂， 以36.5%的产率得到[Cu(2,2'-bis[[(3,5-dimethylpyrazol-1-yl)methyl]amino]-1,1'-biphenyl)(Cl)]Cl
  参考文献：
  名称：

  Copper(II) complexes of a biphenyl-based ligand: Tuning the needs of the metal with those of the ligand

  摘要：

  The novel pyrazole-containing tetradentate ligand 2,2'-bis[[(3,5-dimethylpyrazol-1-yl)methyl]amino]-1,1'-biphenyl (N-4-mpz), 1, was synthesized and three Cu(II) complexes, 2-4, were prepared from this compound. These complexes were characterized by a combination of elemental analysis, FAB-MS and electrochemistry and were shown to have the structure of [Cu(N-4-mpz)(Pz)]X-2 where X = BF4 or ClO4 or [Cu(N-4-mpz)(Cl)]Cl. The X-ray Structure of [Cu(N-4-mpz)(Pz)] (ClO4)(2)center dot CH3OH, 2, was determined and it showed the Cu(II) coordinated by the four nitrogen donors from the ligand along with an exogenous pyrazole donor that had been extracted from another molecule of the ligand. Cyclic voltammetry studies indicated that the complexes undergo quasi-reversible one-electron reductions in acetonitrile at potentials between 396 and 422 mV versus Ag/AgCl. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.poly.2008.11.034

文献信息

• Composition, synthesis and therapeutic applications of polyamines
  申请人：Murphy A Michael

  公开号：US20050085555A1

  公开（公告）日：2005-04-21

  This invention relates to a process of synthesis and composition of open chain (ring), closed ring, linear branched and or substituted polyamines, polyamine derived tyrosine phosphatase inhibitors and PPAR partial agonists/partial antagonists via a series of substitution reactions and optimizing the bioavailability and biological activities of the compounds. Polyamines prevent the toxicty of neutoxins and diabetogenic toxins including paraquat, methyphenyl pyridine radical, rotenone, diazoxide, streptozotocin and alloxan. These polyamines can be to treat neurological, cardiovascular, endocrine acquired and inherited mitochondrial DNA damage diseases and other disorders in mammalian subjects, and more specifically to the therapy of Parkinson's disease, Alzheimer's disease, Lou Gehrig's disease, Binswanger's disease, Olivopontine Cerebellar Degeneration, Lewy Body disease, Diabetes, Stroke, Atherosclerosis, Myocardial Ischemia, Cardiomyopathy, Nephropathy, Ischemia, Glaucoma, Presbycussis, Cancer, Osteoporosis, Rheumatoid Arthritis, Inflammatory Bowel Disease, Multiple Sclerosis and as Antidotes to Toxin Exposure.

  这项发明涉及一种合成和构成开链（环）、闭环、线性分支和/或取代聚胺、聚胺衍生的酪氨酸磷酸酶抑制剂和PPAR部分激动剂/部分拮抗剂的过程，通过一系列的取代反应来优化化合物的生物利用度和生物活性。聚胺可以预防神经毒素和导致糖尿病的毒素的毒性，包括百草枯、甲基苯基吡啶自由基、洛特侬、重组蛋白酶和阿洛克瑞。这些聚胺可以用于治疗哺乳动物主体中的神经系统、心血管系统、内分泌系统获得性和遗传性线粒体DNA损伤疾病以及其他疾病，更具体地用于治疗帕金森病、阿尔茨海默病、路易氏氏病、宾斯旺格氏病、橄榄桥小脑变性、Lewy小体病、糖尿病、中风、动脉粥样硬化、心肌缺血、心肌病、肾病、缺血、青光眼、老年性耳聋、癌症、骨质疏松症、类风湿性关节炎、炎症性肠病、多发性硬化症以及作为毒素暴露的解毒剂。
• Therapeutic polyamine compositions and their synthesis
  申请人：Murphy Michael A.

  公开号：US20140057877A1

  公开（公告）日：2014-02-27

  This invention relates to a process of synthesis and composition of open chain (ring), closed ring, linear branched and or substituted polyamines, polyamine derived tyrosine phosphatase inhibitors and PPAR partial agonists/partial antagonists via a series of substitution reactions and optimizing the bioavailability and biological activities of the compounds. Polyamines prevent the toxicity of neurotoxins and diabetogenic toxins including paraquat, methyphenyl pyridine radical, rotenone, diazoxide, streptozotocin and alloxan. These polyamines can be utilized to treat neurological, cardiovascular, endocrine acquired and inherited mitochondrial DNA damage diseases and other disorders in mammalian subjects, and more specifically to the therapy of Parkinson's disease, Alzheimer's disease, Lou Gehrig's disease, Binswanger's disease, Olivopontine Cerebellar Degeneration, Lewy Body disease, Diabetes, Stroke, Atherosclerosis, Myocardial Ischemia, Cardiomyopathy, Nephropathy, Ischemia, Glaucoma, Presbycussis, Cancer, Osteoporosis, Rheumatoid Arthritis, Inflammatory Bowel Disease, Multiple Sclerosis and as Antidotes to Toxin Exposure.

  本发明涉及一种通过一系列取代反应合成和组成开链（环）、闭合环、线性支链和/或取代的多胺、多胺衍生的酪氨酸磷酸酶抑制剂和PPAR部分激动剂/部分拮抗剂的过程，并优化化合物的生物利用度和生物活性。多胺可以预防神经毒素和糖尿病毒素（包括百草枯、甲基苯基吡啶自由基、罗滕酮、重组胰岛素和阿洛酮）的毒性。这些多胺可用于治疗哺乳动物主体的神经、心血管、内分泌获得性和遗传性线粒体DNA损伤疾病和其他疾病，更具体地说是治疗帕金森病、阿尔茨海默病、路易·格里格病、宾斯旺格病、橄榄桥小脑变性、Lewy体病、糖尿病、中风、动脉粥样硬化、心肌缺血、心肌病、肾病、缺血、青光眼、老年性耳聋、癌症、骨质疏松症、类风湿性关节炎、炎症性肠病、多发性硬化症以及作为毒素暴露的解毒剂。
• COMPOSITION, SYNTHESIS AND THERAPEUTIC APPLICATIONS OF POLYAMINES
  申请人：Murphy, Michael A.

  公开号：EP1465611A2

  公开（公告）日：2004-10-13
• JP2006502081A
  申请人：——

  公开号：JP2006502081A

  公开（公告）日：2006-01-19
• [EN] COMPOSITION, SYNTHESIS AND THERAPEUTIC APPLICATIONS OF POLYAMINES<br/>[FR] COMPOSITION, SYNTHESE ET APPLICATIONS THERAPEUTIQUES DE POLYAMINES
  申请人：MURPHY MICHAEL A

  公开号：WO2003051348A2

  公开（公告）日：2003-06-26

  This invention relates to a process of synthesis and composition of open chain (ring), closed ring, linear branched and or substituted polyamines, polyamine derived tyrosine phosphatase inhibitors and PPAR partial agonists/partial antagonists via a series of substitution reactions and optimizing the bioavailability and biological activities of the compounds. Polyamines prevent the toxicty of neutoxins and diabetogenic toxins including paraquat, methyphenyl pyridine radical, rotenone, diazoxide, streptozotocin and alloxan. These polyamines can be to treat neurological, cardiovascular, endocrine acquired and inherited mitochondrial DNA damage diseases and other disorders in mammalian subjects, and more specifically to the therapy of Parkinson's disease, Alzheimer's disease, Lou Gehrig's disease, Binswanger's disease, Olivopontine Cerebellar Degeneration, Lewy Body disease, Diabetes, Stroke, Atherosclerosis, Myocardial Ischemia, Cardiomyopathy, Nephropathy, Ischemia, Glaucoma, Presbycussis, Cancer, Osteoporosis, Rheumatoid Arthritis, Inflammatory Bowel Disease, Multiple Sclerosis and as Antidotes to Toxin Exposure.